P15^INK4b Gene Methylation and Myelodysplastic Syndromes

References

• Jones P. A. DNA methylation errors and cancer. Cancer Res 1996; 56: 2463–2467
   PubMed Web of Science ®Google Scholar
• Razin A., Shemer R. DNA methylation in early development. Hum Mol Genet. 1995; 1995: 1751–1755, Spec No
   Google Scholar
• Razin A., Kafri T. DNA methylation from embryo to adult. Prog Nucleic Acid Res Mol Biol 1994; 48: 53–81
   PubMed Web of Science ®Google Scholar
• Razin A., Cedar H. DNA methylation and genomic imprinting. Cell 1994; 77: 473–476
   PubMed Web of Science ®Google Scholar
• Razin A. CpG methylation. chromatin structure and gene silencing-a three-way connection. Embo J 1998; 17: 4905–4908
   PubMed Web of Science ®Google Scholar
• Pazin M. J., Kadonaga J. T. What's up and down with histone deacetylation and transcription?. Cell 1997; 89: 325–328
   PubMed Web of Science ®Google Scholar
• Pikaart M. J., Recillas-Targa F., Felsenfeld G. Loss of transcriptional activity of a transgene is accompanied by DNA methylation and histone deacetylation and is prevented by insulators. Genes Dev 1998; 12: 2852–2862
   PubMed Web of Science ®Google Scholar
• Jones P. L., Veenstra G. J., Wade P. A., Vermaak D., Kass S. U., Landsberger N., Strouboulis J., Wolffe A. P. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet 1998; 19: 187–191
   PubMed Web of Science ®Google Scholar
• Cameron E. E., Bachman K. E., Myohanen S., Herman J. G., Baylin S. B. Synergy of demethylation and histone deacetylase inhibition in the re- expression of genes silenced in cancer. Nat Genet 1999; 21: 103–107
   PubMed Web of Science ®Google Scholar
• Rougier N., Bourc'his D., Gomes D. M., Niveleau A., Plachot M., Paldi A., Viegas-Pequignot E. Chromosome methylation patterns during mammalian preimplantation development. Genes Dev 1998; 12: 2108–2113
   PubMed Web of Science ®Google Scholar
• Mostoslavsky R., Singh N., Kirillov A., Pelanda R., Cedar H., Chess A., Bergman Y. Kappa chain monoallelic demethylation and the establishment of allelic exclusion. Genes Dev 1998; 12: 1801–1811
   PubMed Web of Science ®Google Scholar
• Saggioro D., Forino M., Chieco-Bianchi L. Transcriptional block of HTLV-I LTR by sequence-specific methylation. Virology 1991; 182: 68–75
   PubMed Web of Science ®Google Scholar
• Robertson K. D., Ambinder R. F. Methylation of the Epstein-Barr virus genome in normal lymphocytes. Blood 1997; 90: 4480–4484
   PubMed Web of Science ®Google Scholar
• Robertson K. D., Manns A., Swinnen L. J., Zong J. C., Gulley M. L., Ambinder R. F. CpG methylation of the major Epstein-Barr virus latency promoter in Burkitt's lymphoma and Hodgkin's disease. Blood 1996; 88: 3129–3136
   PubMed Web of Science ®Google Scholar
• Jones P. A., Laird P. W. Cancer epigenetics comes of age [In Process Citation]. Nat Genet 1999; 21: 163–167
   PubMed Web of Science ®Google Scholar
• Lengauer C., Kinzler K. W., Vogelslein B. DNA methylation and genetic instability in colorectal cancer cells [see comments]. Proc Natl Acad Sci USA 1997; 94: 2545–2550
   PubMed Web of Science ®Google Scholar
• Ramchandani S., MacLeod A. R., Pinard M., von Hofe E., Szyf M. Inhibition of tumorigenesis by a cytosine-DNA. methyltransferase. antisense oligodeoxynu-cleotide. Proc Natl Acad Sci U S A 1997; 94: 684–689
   PubMed Web of Science ®Google Scholar
• Jones P. A., Gonzalgo M. L. Altered DNA methylation and genome instability: a new pathway to cancer? [comment]. Proc Natl Acad Sci U S A 1997; 94: 2103–2105
   PubMed Web of Science ®Google Scholar
• Baylin S. B., Herman J. G., Graff J. R., Vertino P. M., Issa J. P. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 1998; 72: 141–196
   PubMed Web of Science ®Google Scholar
• Drexler H. G. Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16. p18 and p19 in human leukcmia-lymphoma cells. Leukemia 1998; 12: 845–859
   PubMed Web of Science ®Google Scholar
• Merlo A., Herman J. G., Mao L., Lee D. J., Gabrielson E., Burger P. C., Baylin S. B., Sidransky D. 5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers [see comments]. Nat Med. 1995; 1: 686–692
   PubMed Web of Science ®Google Scholar
• Martinez-Delgado B., Fernandez-Piqueras J., Garcia M. J., Arranz E., Gallego J., Rivas C., Robledo M., Benitez J. Hypermethylation of a 5' CpG island of p16 is a frequent event in non-Hodgkin's lymphoma. Leukemia 1997; 11: 128–425
   PubMedGoogle Scholar
• Herman J. G., Civin C. I., Issa J. P., Collector M. I., Sharkis S. J., Baylin S. B. Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. Cancer Res 1997; 57: 837–841
   PubMed Web of Science ®Google Scholar
• Malumbres M., Péd C. I., Santos J., Meléndez B., Mangues R., Serrano M., Pellicer A., Fernández-Piqueras J. Inactivation of the cyclin-dependent kinase inhibitor p15INK4b by deletion and de novo methylation with independence of p16INK4a alterations in murine primary T-cell lymphomas. Oncogene 1997; 14: 1361–1370
   PubMed Web of Science ®Google Scholar
• Tulchinsky E., Grigorian M., Tkatch T., Georgiev G., Lukanidin E. Transcriptional regulation of the mtsl gene in human lymphoma cells: the role of DNA-methylation. Biochim Biophys Acta 1995; 1261: 243–248
   PubMed Web of Science ®Google Scholar
• Klangby U., Okan I., Magnusson K. P., Wendland M., Lind P., Wiman K. G. P16/ink4a and p15/ink4b gene methylation and absence of p 16/ink4a mRna and protein expression in Burkitt's lymphoma. Blood 1998; 91: 1680–1687
   PubMed Web of Science ®Google Scholar
• Martinez-Delgado B., Robledo M., Arranz E., Osorio A., Garcia M. J., Echezarreta G., Rivas C., Benitez J. Hypermethylation of p15/ink4b/MTS2 gene is differentially implicated among non-Hodgkin's lymphomas. Leukemia 1998; 12: 937–941
   PubMed Web of Science ®Google Scholar
• Zhang S. J., Endo S., Ichikawa T., Washiyama K., Kumanishi T. Frequent deletion and 5' CpG island methylation of the p16 gene in primary malignant lymphoma of the brain. Cancer Res 1998; 58: 1231–1237
   PubMed Web of Science ®Google Scholar
• Villuendas R., Sanchez-Beato M., Martinez J. C., Saez A. I., Martinez-Delgado B., Garcia J. F., Mateo M. S., Sanchez-Verde L., Benitez J., Martinez P., Piris M. A. Loss of p16/INK4A protein expression in non-Hodgkin's lymphomas is a frequent finding associated with tumor progression. Am J Pathol 1998; 153: 887–897
   PubMed Web of Science ®Google Scholar
• Tasaka T., Berenson J., Vescio R., Hirama T., Miller C. W., Nagai M., Takahara J., Koeffler H. P. Analysis of the p16(INK4A). p15(INK4B) and p18(INK4C) genes in multiple myeloma. British Journal of Haematology 1997; 96: 98–102
   PubMed Web of Science ®Google Scholar
• Ng M. H., Chung Y. F., Lo K. W., Wickham N. W., Lee J. C., Huang D. P. Frequent hypermethylation of p16 and p15 genes in multiple myeloma. Blood 1997; 89: 2500–2506
   PubMed Web of Science ®Google Scholar
• Wong I. H., Ng M. H., Lee J. C., Lo K. W., Chung Y. F., Huang D. P. Transcriptional silencing of the p16 gene in human myeloma-derived cell lines by hypermethylation [In Process Citation]. Br J Haematol 1998; 103: 168–175
   PubMed Web of Science ®Google Scholar
• Herman J. G., Merlo A., Mao L., Lapidus R. G., Issa J. P., Davidson N. E., Sidransky D., Baylin S. B. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 1995; 55: 4525–4530
   PubMed Web of Science ®Google Scholar
• Herman J. G., Jen J., Merlo A., Baylin S. B. Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B. Cancer Res 1996; 56: 722–727
   PubMed Web of Science ®Google Scholar
• Jonveaux P., Fenaux P., Quiquandon I., Pignon J. M., Laï J. M., Loucheux-Lefebvre M. H., Goossens M., Bauters F., Berger R. Mutations in the p53 gene in myelodysplastic syndromes. Oncogene. 1991; 6: 2243–2247
   PubMed Web of Science ®Google Scholar
• Wattel E., Preudhomme C., Hecquet B., Vanrumbeke M., Quesnel B., Dervite I., Morel P., Fenaux P. P53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 1994; 84: 3148–3157
   PubMed Web of Science ®Google Scholar
• Quesnel B., Preudhomme C., Philippe N., Vanrumbeke M., Dervite I., Lai J. L., Bauters F., Wattel E., Fenaux P. P16 gene homozygous deletions in acute lymphoblastic leukemia. Blood 1995; 85: 657–663
   PubMed Web of Science ®Google Scholar
• Quesnel B., Preudhomme C., Fenaux P. P16Ink4A gene and hematological malignancies. Leuk Lymphoma 1996; 22: 11–24
   PubMed Web of Science ®Google Scholar
• Nakamaki T., Bartram C., Seriu T., Kahan J., Fukuchi K., Tsuruoka N., Janssen J. W., Miller C. W., Koeffler H. P. Molecular analysis of the cyclin-dependent kinase inhibitor genes, p15, p16. p18 and p19 in the myelodysplastic syndromes. Leuk Res 1997; 21: 235–240
   PubMed Web of Science ®Google Scholar
• Quesnel B., Guillerm G., Vereecque R., Wattel E., Preudhomme C., Bauters F., Vanrumbeke M., Fenaux P. Methylation of the p15 gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood 1998; 91: 2985–2990
   PubMed Web of Science ®Google Scholar
• Uchida T., Kinoshita T., Nagai H., Nakahara Y., Saito H., Hotta T., Murate T. Hypermethylation of the p15(INK4B) gene in myelodysplastic syndromes. Blood 1997; 90: 1403–1409
   PubMed Web of Science ®Google Scholar
• Uchida T., Ohashi H., Kinoshita T., Sailo H., Taguchi R., Hotta T., Murate T. Hypermethylation of p15(INK4B) gene in a patient with acute myelogenous leukemia evolved from paroxysmal nocturnal hemoglobinuria [letter]. Blood 1998; 92: 2981–2983
   PubMed Web of Science ®Google Scholar
• Whitman M. Smads and early developmental signaling by the TGFbeta superfamily. Genes Dev 1998; 12: 2445–2462
   PubMed Web of Science ®Google Scholar
• Ramsfjell V., Borge O. J., Cui L., Jacobsen S. E. Thrombopoietin directly and potently stimulates multilineage growth and progenitor cell expansion from primitive (CD34+ CD38-) human bone marrow progenitor cells: distinct and key interactions with the ligands for c-kit and flt3. and inhibitory effects of TGF-beta and TNF-alpha. J Immunol 1997; 158: 5169–5177
   PubMed Web of Science ®Google Scholar
• Bonnet D., Lemoine F. M., Najman A., Guigon M. Comparison of the inhibitory effect of AcSDKP. TNF-alpha. TGF-beta, and MIP-1 alpha on marrow-purified CD34+ progenitors. Exp Hematol 1995; 23: 551–556
   PubMed Web of Science ®Google Scholar
• Lardon F., Snoeck H. W., Nijs G., Lenjou M., Peetermans M. E., Rodrigus I., Berneman Z. N., Van Bockstaele D. R. Transforming growth factor-beta regulates the cell cycle status of interleukin-3 (IL-3) plus IL-1, stem cell factor, or IL-6 stimulated CD34+ human hematopoietic progenitor cells through different cell kinetic mechanisms depending on the applied stimulus. Exp Hematol 1994; 22: 903–909
   PubMed Web of Science ®Google Scholar
• Mayani H., Little M. T., Dragowska W., Thornbury G., Lansdorp P. M. Differential effects of the hematopoietic inhibitors MIP- 1 alpha, TGF-beta, and TNF-alpha on cytokine-induced proliferation of subpopulations of CD34+ cells purified from cord blood and fetal liver. Exp Hematol 1995; 23: 422–427
   PubMed Web of Science ®Google Scholar
• Van Ranst P. C., Snoeck H. W., Lardon F., Lenjou M., Nijs G., Weekx S. F., Rodrigus I., Berneman Z. N., Van Bockstaele D. R. TGF-beta and MIP-1 alpha exert their main inhibitory activity on very primitive CD34+2CD38-cells but show opposite effects on more mature CD34+CD38+ human hematopoietic progenitors. Exp Hematol 1996; 24: 1509–1515
   PubMed Web of Science ®Google Scholar
• Imbert A. M., Bagnis C., Galindo R., Chabannon C., Mannoni P. A neutralizing anti-TGF-beta 1 antibody promotes proliferation of CD34+Thy-1 + peripheral blood progenitors and increases the number of transduced progenitors. Exp Hematol 1998; 26: 374–381
   PubMed Web of Science ®Google Scholar
• Bruno E., Horrigan S. K., Van Den Berg D., Rozler E., Fitting P. R., Moss S. T., Westbrook C., Hoffman R. The Smad5 gene is involved in the intracellular signaling pathways that mediate the inhibitory effects of transforming growth factor-beta on human hematopoiesis. Blood 1998; 91: 1917–1923
   PubMed Web of Science ®Google Scholar
• Li M. L., Cardoso A. A., Sansilvestri P., Hatzfeld A., Brown E. L., Sookdeo H., Levesque J. P., Clark S. C., Hatzfeld J. Additive effects of steel factor and antisense TGF-beta 1 oligodeoxynucleotide on CD34+ hematopoietic progenitor cells. Leukemia 1994; 8: 441–445
   PubMed Web of Science ®Google Scholar
• Cardoso A. A., Li M. L., Batard P., Hatzfeld A., Brown E. L., Levesque J. P., Sookdeo H., Panterne B., Sansilvestri P., Clark S. C., et al. Release from quiescence of CD34+ CD38- human umbilical cord blood cells reveals their potentiality to engraft adults. Proc Natl Acad Sci U S A 1993; 90: 8707–8711
   PubMed Web of Science ®Google Scholar
• Drexler H. G. Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells. Leukemia 1996; 10: 588–599
   PubMed Web of Science ®Google Scholar
• Sott C., Dorner B., Karawajew L., Herrmann F., Brach M. A. Transforming growth factor-beta relieves stem cell factor- induced proliferation of myelogenous leukemia cells through inhibition of binding of the transcription factor NF-jun. Blood 1994; 84: 1950–1959
   PubMed Web of Science ®Google Scholar
• Murohashi I., Endho K., Nishida S., Yoshida S., Jinnai I., Bessho M., Hirashima K. Differential effects of TGF-beta 1 on normal and leukemic human hematopoietic cell proliferation. Exp Hematol 1995; 23: 970–977
   PubMed Web of Science ®Google Scholar
• Kurokawa M., Mitani K., Imai Y., Ogawa S., Yazaki Y., Hirai H. The t(3;21) fusion product, AML1/Evi-1, interacts with Smad3 and blocks transforming growth factor-beta-mediated growth inhibition of myeloid cells. Blood 1998; 92: 4003–40012
   PubMed Web of Science ®Google Scholar
• Sasaki H., Matsuda M., Lu Y., Ikuta K., Matsuyama S., Hirabayashi Y., Mitsui H., Matsumura T., Muramatsu M., Tsukada T., Aizawa S., Inoue. A fraction unresponsive to growth inhibition by TGF-beta among the high-proliferative potential progenitor cells in bone marrow of p53-deficient mice. Leukemia 1997; 11: 239–244
   PubMed Web of Science ®Google Scholar
• Drexler H. G., Meyer C., Zaborski M., Uphoff C. C., Quentmeier H. Growth-inhibitory effects of transforming growth factor-beta 1 on myeloid leukemia cell lines. Leuk Res 1998; 22: 927–938
   PubMed Web of Science ®Google Scholar
• Cá J, Zentella A., Massagué J. Disruption of transforming growth factor beta signaling by a mutation that prevents transphosphorylation within the receptor complex. Mol Cell Biol 1995; 15: 1573–1581
   PubMed Web of Science ®Google Scholar
• Guo Y., Kyprianou N. Overexpression of transforming growth factor (TGF) beta1 type II receptor restores TGF-beta 1 sensitivity and signaling in human prostate cancer cells. Cell Growth Differ 1998; 9: 185–193
   PubMedGoogle Scholar
• Wieser R., Gruber B., Rieder H., Fonatsch C. Mutational analysis of the tumor suppressor Smad2 in acute lymphoid and myeloid leukemia. Leukemia 1998; 12: 1114–1118
   PubMed Web of Science ®Google Scholar
• Grady W. M., Rajput A., Myeroff L., Liu D. F., Kwon K., Willis J., Markowitz S. Mutation of the type II transforming growth factor-beta receptor is coincident with the transformation of human colon adenomas to malignant carcinomas. Cancer Res 1998; 58: 3101–3104
   PubMed Web of Science ®Google Scholar
• Zagonel V., Lo Re G., Marotta G., Babare R., Sardeo G., Gattei V., De Angelis V., Monfardini S., Pinto A. 5-Aza-2'-deoxycytidine (Decitabine) induces trilineage response in unfavourable myelodysplastic syndromes. Leukemia 1993; 7(Suppl 1)30–35
   PubMed Web of Science ®Google Scholar
• Pinto A., Zagonel V. 5-Aza-2'-deoxycytidine (Decitabine) and 5-azacytidine in the treatment of acute myeloid leukemias and myelodysplastic syndromes: past, present and future trends. Leukemia 1993; 7(Suppl 1)51–60
   PubMed Web of Science ®Google Scholar
• Cheson B. D. Standard and low-dose chemotherapy for the treatment of myelodysplastic syndromes. Leuk Res. 1998; 22(Suppl 1)S17–21
   PubMed Web of Science ®Google Scholar
• Wijermans P. W., Krulder J. W., Huijgens P. C., Neve P. Continuous infusion of low-dose 5-Aza-2'-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome. Leukemia 1997; 11(Suppl 1)S19–23
   PubMedGoogle Scholar
• Daskalis M., Nguyen T. T., Wijermans P., Jones P. A., M. L. Frequent hypermethylation of p15INK4b in patients with myelodysplastic syndromes is decreased following treatment with 5-Aza-2'deoxycytidine (decitabine). American Society of Hematology, Fortieth Annual meeting, Blood. Miami 1998; Vol. 92, p. Abstract 2937
   Google Scholar
• Yeager T. R., DeVries S., Jarrard D. F., Kao C., Nakada S. Y., Moon T. D., Bruskewitz R., Stadler W. M., Meisner L. F., Gilchrist K. W., Newton M. A., Waldman F. M., Reznikoff C. A. Overcoming cellular senescence in human cancer pathogenesis. Genes Dev 1998; 12: 163–174
   PubMedGoogle Scholar